Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Brian S. Bryzinski"'
Publikováno v:
Journal of Diabetes and its Complications. 28:887-893
Aims To examine whether concomitant statin therapy affects glycemic control with saxagliptin 2.5 and 5mg/d in patients with type 2 diabetes mellitus (T2DM). Methods Efficacy and safety were analyzed post hoc for pooled data from 9 saxagliptin randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47722cd47e90d9dfe30cad1c7a6eebf4
https://doi.org/10.1016/j.jdiacomp.2014.07.006
https://doi.org/10.1016/j.jdiacomp.2014.07.006
Publikováno v:
Postgraduate Medicine. 126:19-32
To test the effectiveness and safety of saxagliptin 5 mg/d in patients with type 2 diabetes mellitus (T2DM) with and without history of cardiovascular disease (CVD) or cardiovascular (CV) risk factors.The authors conducted a post hoc analysis of data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ace8373da2c484f410c1bd9fcb14024
https://doi.org/10.3810/pgm.2014.10.2818
https://doi.org/10.3810/pgm.2014.10.2818
Publikováno v:
Postgraduate Medicine. 125:145-154
This post hoc analysis sought to assess the efficacy, safety, and tolerability of saxagliptin in patients with type 2 diabetes mellitus and cardiovascular (CV) risk factors or disease (CVD).Data from 5 randomized controlled trials were pooled to comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bacfaa08bc29ed6ddd074328cb8cfcab
https://doi.org/10.3810/pgm.2013.05.2657
https://doi.org/10.3810/pgm.2013.05.2657
Publikováno v:
Diabetes and Vascular Disease Research. 4:181-193
The efficacy and safety of tesaglitazar (0.5 and 1 mg) and pioglitazone (15, 30 and 45 mg) were compared in a 24-week, randomised, double-blind study in 1, 707 patients with type 2 diabetes mellitus. Tesaglitazar 1 mg was non-inferior to pioglitazone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dd9783724a96a9fde2cb50e49d11683
https://doi.org/10.3132/dvdr.2007.039
https://doi.org/10.3132/dvdr.2007.039
Publikováno v:
Journal of Diabetes and Metabolism.
Objective: Saxagliptin is a once-daily, orally administered dipeptidyl peptidase-4 inhibitor, approved for the treatment of type 2 diabetes mellitus (T2DM). In 4 double-blind, placebo-controlled, phase 3 trials, saxagliptin 2.5 or 5 mg significantly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc571497d972d56f01c596e2c85f6524
https://doi.org/10.4172/2155-6156.1000524
https://doi.org/10.4172/2155-6156.1000524
Publikováno v:
Nutrition, metabolism, and cardiovascular diseases : NMCD. 26(5)
To assess the efficacy and safety of saxagliptin 2.5 and 5 mg/d in patients with type 2 diabetes mellitus (T2DM) and high risk of coronary heart disease (CHD) or stroke as estimated by the United Kingdom Prospective Diabetes Study (UKPDS) risk engine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14af1be756c6af05ba91e02b7069cfa8
https://pubmed.ncbi.nlm.nih.gov/27033025
https://pubmed.ncbi.nlm.nih.gov/27033025
Autor:
Brian S. Bryzinski, Matthew R. Weir, Joseph S. Simon, William H. Frishman, Shun-Yi Chen, Demissie Alemayehu, James F. Burris, William J. Mroczek
Publikováno v:
The Journal of Clinical Pharmacology. 35:182-188
This 30-center, randomized, double-blind, placebo-controlled, parallel-group study was designed to (1) establish that 6.25 mg of hydrochlorothiazide (HCTZ) given once daily with 5 mg of bisoprolol fumarate can contribute to antihypertensive effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1faf9e82f5d737febaaac87e2839884d
https://doi.org/10.1002/j.1552-4604.1995.tb05009.x
https://doi.org/10.1002/j.1552-4604.1995.tb05009.x
Autor:
Albert A. Carr, B McKee, M Desnoyers, Miguel A. Zinny, D M O'Donnell, B R Nelson, L M Prisant, R J Westcott, Brian S. Bryzinski
Publikováno v:
The Journal of Clinical Pharmacology. 30:1096-1101
Twenty-six patients with mild-to-moderate essential hypertension participated in a 6-week outpatient, multicenter, randomized, double-blind, placebo-controlled two-way crossover study to assess the hemodynamic effects of bisoprolol (20 mg QD) at stea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8185a36e2301987f3cb536812ecc9926
https://doi.org/10.1002/j.1552-4604.1990.tb01851.x
https://doi.org/10.1002/j.1552-4604.1990.tb01851.x
Autor:
James M. McKenney, Valerie A. Cain, James W. Blasetto, Brian S Bryzinski, M Angeli Adamczyk, Peter B. Jones
Publikováno v:
Current medical research and opinion. 19(8)
In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared with that of atorvastatin (Lipitor), simvastatin (Zocor), and pravastatin (Pravachol)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5f951d833aaed8621360c9a921a7d5f
https://pubmed.ncbi.nlm.nih.gov/14687438
https://pubmed.ncbi.nlm.nih.gov/14687438
Autor:
Jerry G. Blaivas, Alan J. Wein, Asnat Groutz, Brian S Bryzinski, David C. Chaikin, Neil M. Resnick, Deborah Anzalone, Kurt Engleman
Publikováno v:
The Journal of urology. 164(3 Pt 1)
We assessed the test-retest reliability of a 24, 48 and 72-hour micturition diary and pad test in patients referred for the evaluation of urinary incontinence and lower urinary tract symptoms.We prospectively enrolled 109 patients referred for the ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cbd296174f64c17a9f02fd91677db10
https://pubmed.ncbi.nlm.nih.gov/10953128
https://pubmed.ncbi.nlm.nih.gov/10953128